The global oral anti-diabetic drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The significant growth in the market can be attributed to factors such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. In 2019, it was estimated that out of 511 million people suffering from diabetes, 31.3% were undiagnosed. In 2019, diabetes was the cause of 4.2 million deaths per year, making it the eighth leading cause of death, globally. The diabetic condition, on the whole, doubles the risk of death. Currently, about 10% of all diabetes cases are Type-1 and the remaining are of Type-2. Thus, the rise in the prevalence of type-2 diabetes globally is likely to create a vast demand for diabetes drugs during the forecast period. 

The global oral anti-diabetic drug market analysis includes some of the key market players such as Sanofi S.A., Eli Lilly and Company, AstraZeneca plc., Astellas Pharma Inc., and Johnson & Johnson (Janss en Pharmaceuticals), among others. To maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. In May 2018, Oramed started working to bring the first oral insulin product to market, providing a more convenient, effective and safer method for delivering insulin therapy.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Bausch Health Companies Inc., Nestlé (Galderma), Leo Pharma Inc., Hovione FarmaCiencia SA, and Aclaris Therapeutics, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Oral Anti Diabetic Drug Market by Segment

By Drugs 

• Biguanides

• Alpha-glucosidase inhibitors

• Dopamine-D2 receptor agonists

• Sodium-glucose Cotransport -2 (SGLT-2) inhibitor

• Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors

• Sulfonylureas

• Meglitinides

Global Oral Anti Diabetic Drug Market by Regional Analysis